- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Vimta Labs Limited reported strong Q2 FY25 financial results, achieving total income of ₹854 million, a 26.4% increase year-over-year. EBITDA rose by 57.3% to ₹306 million, with margins at 35.8%. The PAT surged to ₹170 million, reflecting a 109.9% increase. For H1 FY25, total income reached ₹1,610 million, with a PAT of ₹309 million. The company focuses on enhancing pharmaceutical and testing services after divesting its Diagnostic and Pathological services business.